MicroRNA‑144 suppresses aggressive phenotypes of tumor cells by targeting ANO1 in colorectal cancer

Jiang, Yasu; Cai, Yunhui; Shao, Weiwei; Li, Feng; Guan, Zongyu; Zhou, Yi; Tang, Chong; Feng, Shichun

doi:10.3892/or.2019.7025

Cited by 24 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is tempting to speculate that low miR-144-3p blood levels are due to the adaptive selection of aggressive CRC cell populations. Potential targets of miR-144-3p in CRC are anoctamin 1 (ANO1) [ 47 ], MAD Homolog 4 (SMAD4) [ 48 ] and Rho-associated coiled-coil containing protein kinase 1 (ROCK1) [ 46 , 49 ]. Likewise, miR-486-5p down-regulation in blood mirrors its low expression (relative to normal), previously seen in tumor tissues from early as well as advanced CRC stages [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery

Gasparello

Papi

Allegretti

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: Liquid biopsy (LB) provides an examination of the peripheral blood of cancer patients for circulating tumor cells, cell-free nucleic acids and microRNAs (miRNAs) and is an established tool of precision medicine. Unlike most previous LB studies that focused on advanced metastatic colorectal cancer (CRC), we assessed miRNA dysregulation in blood samples obtained on the day of surgery from patients with primary CRC lesions but no clinical evidence of extra-colonic diffusion. In this study, plasma preparation included miRNAs associated to exosomes, but excluded large macrovesicles from the preparation. Methods: The miRNA profile in plasma isolated from a cohort of 35 CRC patients at the day of surgery was analyzed by Next Generation Sequencing (NGS) and further confirmed by droplet digital RT-PCR (dd-RT-PCR). Results: A miR-141-3p/miR-221-3p/miR-222-3p upregulation signature previously described in advanced CRC did not discriminate the analyzed early-CRC cohort from six tumor-free donors (Tf-D). In contrast, NGS-based miRNome analysis of a training cohort of five CRC and three tumor-free donors identified a novel, distinct nine miRNA signature comprising five up-regulated and four down-regulated miRNAs, six of which could be confirmed in the full CRC and tumor-free donor validation dataset by dd-RT-PCR. Additionally, a KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) mutant status was correlated with the plasma content of three identified miRNAs. Conclusions: When the data obtained were comparatively evaluated, at least one of the miRNAs belonging to the signature list was found to be dysregulated in 34/35 (97.1%) of our early-CRC plasma samples. The miRNA list provides diagnostic markers as well as possible molecular targets for protocols focusing on “microRNA therapeutics”.

show abstract

Section: Discussionmentioning

confidence: 99%

A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery

Gasparello

Papi

Allegretti

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Mir-144 could be one epigenetic regulator of mediatization, since Anoctamin 1 (ANO1), a miR-144 target gene that is located on chromosome 11q13, is involved in various biological processes, including angiogenesis, chemotaxis, and adherence. Moreover, the downregulation of miR-144, through the targeting of ANO1, leads to the activation of the epidermal growth factor receptor (EGFR) or MAP kinase signaling pathways, two of the main driver pathways involved in CRC [75].…”

Section: Mir-144 In Colorectal Cancermentioning

confidence: 99%

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

Kooshkaki

Rezaei

Rahmati

et al. 2020

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small and non-coding RNAs that display aberrant expression in the tissue and plasma of cancer patients when tested in comparison to healthy individuals. In past decades, research data proposed that miRNAs could be diagnostic and prognostic biomarkers in cancer patients. It has been confirmed that miRNAs can act either as oncogenes by silencing tumor inhibitors or as tumor suppressors by targeting oncoproteins. MiR-144s are located in the chromosomal region 17q11.2, which is subject to significant damage in many types of cancers. In this review, we assess the involvement of miR-144s in several cancer types by illustrating the possible target genes that are related to each cancer, and we also briefly describe the clinical applications of miR-144s as a diagnostic and prognostic tool in cancers.Int. J. Mol. Sci. 2020, 21, 2578 2 of 23 of a mRNA molecule [3]. MiRNAs indicate a new perspective in the study of cancers. More than 50% of miRNA genes were discovered to be located within the genomic regions that are involved in cancers, suggesting their role in human cancer pathogenesis. In pathological conditions, MiRNAs can negatively regulate gene expression and they are associated with tumor growth, apoptosis, invasion, and metastasis. In the past, several studies have indicated the ability of miRNAs in the inhibition of tumors as a critical option for the improvement of cancer therapy [4,5]. Tumor activator miRNAs, called oncomiRs, are overexpressed in various cancers. On the contrary, suppressive tumor miRNAs are underexpressed [6][7][8]. Among several miRNAs assessed, miR-144s seem to have a role in several cancers. These miRNAs are located in the chromosomal region 17q11.2, being significantly destroyed in many types of cancers. The predicted stem-loop structure of miR-144s recognized by the miRBase (http://mirbase.org/) is shown in Figure 1A. The miR-144 hairpin gives rise to the "guide strand" miR-144-5p and the sister "passenger" strand miR-144-3p ( Figure 1B).

show abstract

“…However, forced hypermethylation of the positively correlated CpG island in normal oral keratinocytes by transfection with HPV oncoprotein E7 that recruits DNA methyl transferases (Sen et al, 2018) had no effect on ANO1 expression, demonstrating a disconnect between the in vivo and in vitro findings (Finegersh et al, 2017). ANO1 translation is controlled by a number of microRNAs, including miR-9 in human bronchial epithelial cells (Sonneville et al, 2017), miR-9, miR-132 and miR-144 in colorectal cancer cells (Mokutani et al, 2016;Jiang et al, 2019;Park et al, 2019), and miR-381 in gastric cancer cells (Cao et al, 2017). In addition, alternative splicing of ANO1 in a tissue specific manner affects electrophysiological properties of the channel (Ferrera et al, 2009(Ferrera et al, , 2011Mazzone et al, 2011;O'Driscoll et al, 2011;Ertongur-Fauth et al, 2014;Ohshiro et al, 2014;Strege et al, 2015;Sung et al, 2016).…”

Section: Regulation Of Ano1 Expressionmentioning

confidence: 99%

“…ANO1 translation is controlled by a number of microRNAs, including miR-9 in human bronchial epithelial cells ( Sonneville et al, 2017 ), miR-9, miR-132 and miR-144 in colorectal cancer cells ( Mokutani et al, 2016 ; Jiang et al, 2019 ; Park et al, 2019 ), and miR-381 in gastric cancer cells ( Cao et al, 2017 ). In addition, alternative splicing of ANO1 in a tissue specific manner affects electrophysiological properties of the channel ( Ferrera et al, 2009 , 2011 ; Mazzone et al, 2011 ; O’Driscoll et al, 2011 ; Ertongur-Fauth et al, 2014 ; Ohshiro et al, 2014 ; Strege et al, 2015 ; Sung et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Calcium-Activated Chloride Channel ANO1/TMEM16A: Regulation of Expression and Signaling

Dulin

2020

Front. Physiol.

View full text Add to dashboard Cite

Anoctamin-1 (ANO1), also known as TMEM16A, is the most studied member of anoctamin family of calcium-activated chloride channels with diverse cellular functions. ANO1 controls multiple cell functions including cell proliferation, survival, migration, contraction, secretion, and neuronal excitation. This review summarizes the current knowledge of the cellular mechanisms governing the regulation of ANO1 expression and of ANO1-mediated intracellular signaling. This includes the stimuli and mechanisms controlling ANO1 expression, agonists and processes that activate ANO1, and signal transduction mediated by ANO1. The major conclusion is that this field is poorly understood, remains highly controversial, and requires extensive and rigorous further investigation.

show abstract

MicroRNA‑144 suppresses aggressive phenotypes of tumor cells by targeting ANO1 in colorectal cancer

Cited by 24 publications

References 35 publications

A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery

A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

Calcium-Activated Chloride Channel ANO1/TMEM16A: Regulation of Expression and Signaling

Contact Info

Product

Resources

About